Abstract Number: 2527 • 2019 ACR/ARP Annual Meeting
Cytokine and Autoantibody Profiles During Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
Background/Purpose: The anti-BAFF monoclonal belimumab is approved for the treatment of systemic lupus erythematosus (SLE) since 2011. Effects of belimumab on anti-double stranded (ds)DNA levels,…Abstract Number: 2562 • 2019 ACR/ARP Annual Meeting
Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta-analyses of Observational Studies Published Between 1979 and 2018
Background/Purpose: The impact of glucocorticoid (GC) use on major organ damage in SLE patients has not been formally studied by amalgamating the relevant data published…Abstract Number: 2811 • 2019 ACR/ARP Annual Meeting
The IRE1α Pathway Mediates Neutrophil Stress and NETosis in Lupus
Background/Purpose: Immune complex (IC)-activated neutrophils appear to amplify inflammation in lupus through the release of neutrophil extracellular traps (NETosis). There is presently no consensus as…Abstract Number: 2045 • 2019 ACR/ARP Annual Meeting
RNA Sequencing of Plasma and Urine-derived Extracellular Vesicles from Lupus Nephritis Patients Identifies Disease-associated Small RNA Signatures and Putative Therapeutic Targets
Background/Purpose: Systemic lupus erythematosus is an autoimmune disease characterized by chronic inflammation. We have previously shown that TLR7 and TLR8 are significantly upregulated in PBMCs…Abstract Number: 77 • 2019 ACR/ARP Annual Meeting
Flux Analysis Reveals Influence of Rab4 Expression on Mitochondrial and Pentose Phosphate Pathway Metabolism of Lupus T Cells
Background/Purpose: HRES-1/Rab4 is a small GTPase enzyme which regulates endosomal trafficking. The protein is overexpressed in T cells of SLE patients (J Immunol. February 15,…Abstract Number: 650 • 2019 ACR/ARP Annual Meeting
Performance of the Proposed American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Lupus Erythematosus in Korean Patients
Background/Purpose: To evaluate the performance of the proposed American College of Rheumatology/European League against Rheumatism (ACR/EULAR) classification criteria for systemic lupus erythematosus (SLE) in Korean…Abstract Number: 834 • 2019 ACR/ARP Annual Meeting
Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges
Background/Purpose: There is growing interest in the implementation of patient-reported outcome measures (PROMs) in clinical rheumatology to promote patient-centered care and to meet the mandates…Abstract Number: 1029 • 2019 ACR/ARP Annual Meeting
Epstein-Barr Virus Interleukin 10 in SLE Pathogenesis
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterized by periods of elevated and suppressed disease activity. Epstein Barr Virus (EBV) has been…Abstract Number: 1188 • 2019 ACR/ARP Annual Meeting
Novel PET-Coronary Flow Reserve Imaging to Assess for Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus Compared to Subjects with Diabetes Mellitus and Controls
Background/Purpose: High risk of premature cardiovascular disease (CVD) among SLE patients is well documented, but the best means to detect the earliest stages of CVD…Abstract Number: 1586 • 2019 ACR/ARP Annual Meeting
All-cause Hospitalizations and Mortality in Systemic Lupus Erythematosus in the US- results from a National Inpatient Database
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disorder with variable presentation. While several studies have outlined the risk factors for hospitalization and…Abstract Number: 1624 • 2019 ACR/ARP Annual Meeting
Progression and Factors Associated with Damage Accrual in a SLE Inception Cohort of Hispanic Patients
Background/Purpose: The aims of our study were to determine the cumulative prevalence of damage at baseline, 5 years and 10 years of follow-up, to identify…Abstract Number: 1914 • 2019 ACR/ARP Annual Meeting
Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature
Background/Purpose: The interferon (IFN) signature in SLE is well established, distinguishing lupus patients from healthy controls. Additionally, within lupus patients, higher levels of IFN-responsive gene…Abstract Number: 2127 • 2019 ACR/ARP Annual Meeting
Diagnosis of Inflammatory Rheumatic Diseases: Preliminary Approach by Urine Metabolomics
Background/Purpose: Early diagnosis of inflammatory rheumatic diseases (IRD), as axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) represents in our days a…Abstract Number: 2528 • 2019 ACR/ARP Annual Meeting
Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis
Background/Purpose: Hydroxychloroquine(HCQ) is recommended for all patients with SLE in EULAR recommendation 2019, however, there are not enough data about the effect of additional HCQ…Abstract Number: 2563 • 2019 ACR/ARP Annual Meeting
PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease
Background/Purpose: Anifrolumab, a fully human anti–IFN Type I receptor mAb, is under investigation for the treatment of SLE at a dose of 300 mg intravenously…
- « Previous Page
- 1
- …
- 100
- 101
- 102
- 103
- 104
- …
- 119
- Next Page »